Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ILLUMINATE-HS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 01 Apr 2026 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2026 Planned End Date changed from 29 Nov 2025 to 30 Sep 2026.
- 06 Feb 2026 Planned primary completion date changed from 29 Nov 2025 to 30 Sep 2026.